ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access
Keerthana Chandrasekar, T Navaswetha, Hemalatha Vasudevan, S. Naveen Kumar and K.P. Arun
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
Article Number: 7638 | © The Author(s). 2022
J Pure Appl Microbiol. 2022;16(4):2303-2309. https://doi.org/10.22207/JPAM.16.4.20
Received: 24 February 2022 | Accepted: 05 September 2022 | Published online: 19 October 2022
Issue online: December 2022
Abstract

Amikacin is an aminoglycoside antibiotic with a broad-spectrum bacterial coverage that is frequently utilized both as monotherapy and in combination with other antibiotics for severe bacterial infections in the paediatric population. The narrow therapeutic index of the drug and high inter-individual variabilities in drug exposure results in either drug toxicity or subtherapeutic concentrations. Thus, therapeutic drug monitoring and population pharmacokinetics are pivotal to facilitate the optimal dosage regimens in paediatrics and negate the adverse outcomes. The therapeutic goal is to maintain the target peak and trough concentrations within 30-40mg/l and <5 mg/l respectively. This review aimed to summarize population pharmacokinetic considerations and the pharmacokinetic parameters of amikacin across the paediatric population.

Keywords

Amikacin, Paediatric, Population Pharmacokinetics, Therapeutic Drug Monitoring

Article Metrics

Article View: 178

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.